Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21789645 | 0.87 | TSHR (0.51) | TSHRHPGD | |
| SCHEMBL2955795 | 0.80 | FUCA1 (0.60) | FUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL26990684 | 0.78 | FUCA1 (0.47) | TSHRHPGDLMNAMAPTMAPK1 | |
| SCHEMBL3831241 | 0.78 | FUCA1 (0.47) | TSHRHPGDLMNAMAPTMAPK1 | |
| SCHEMBL6202791 | 0.77 | TSHR (0.58) | TSHRHPGD | |
| SCHEMBL20488466 | 0.76 | FUCA1 (0.60) | FUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL18339637 | 0.75 | FUCA1 (0.55) | TSHRHPGDFUCA1S1PR1S1PR5 | |
| SCHEMBL31327374 | 0.75 | FUCA1 (0.55) | TSHRHPGDFUCA1S1PR1S1PR5 | |
| Hydrochloric Acid SCHEMBL20488123 | 0.75 | FUCA1 (0.58) | TSHRFUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL2962712 | 0.75 | FUCA1 (0.58) | TSHRHPGDFUCA1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589934-B1 | Methods of treatment of non insulin dependent diabetes mellitus, antagonists of the delayed rectifier potassium channel Kv2.1, methods of using and preparing the antagonists and assays for identifying such antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-07-08 | — | — | US | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1042322-B1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2002-04-17 | — | — | EP | disclosed |
| EP-1042322-A1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032487-A1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1999-07-01 | — | — | WO | disclosed |
| US-5110933-A | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof | BOARD OF REGENTS OF OKLAHOMA STATE UNIVERSITY (US) | 1992-05-05 | — | — | US | disclosed |
| US-5084572-A | Cardiovascular disorders | BOARD OF REGENTS OF OKLAHOMA STATE UNIVERSITY (US) | 1992-01-28 | — | — | US | disclosed |